New drug candidate BL-B01D1 enters early human testing for tough cancers
NCT ID NCT05393427
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-phase study tests a new drug called BL-B01D1 in people with advanced urinary or other solid tumors that cannot be cured or have no standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Only 4 participants are enrolled, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTHER SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Peking University First Hospital
Beijing, Beijing Municipality, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.